LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Do patients with large vessel occlusion ischemic stroke harboring prestroke disability benefit from thrombectomy?

    Larsson, Alice / Karlsson, Camilla / Rentzos, Alexandros / Schumacher, Marcus / Abrahamson, Margareta / Allardt, Arne / Brederlau, Anke / Ceder, Erik / Davidson, Maria / Dunker, Dennis / Gunnarsson, Thorsteinn / Holmegaard, Lukas / Jerndal, Mikael / Karlsson, Jan-Erik / Nordanstig, Annika / Redfors, Petra / Rosengren, Lars / Tatlisumak, Turgut / Jood, Katarina

    Journal of neurology

    2020  Volume 267, Issue 9, Page(s) 2667–2674

    Abstract: Objectives: Evidence of endovascular treatment (EVT) for acute large vessel occlusion (LVO) ischemic stroke in patients harboring substantial prestroke disability is lacking due to their exclusion from randomized trials. Here, we used routine care ... ...

    Abstract Objectives: Evidence of endovascular treatment (EVT) for acute large vessel occlusion (LVO) ischemic stroke in patients harboring substantial prestroke disability is lacking due to their exclusion from randomized trials. Here, we used routine care observational data to compare outcomes in patients with and without prestroke disability receiving EVT for LVO ischemic stroke.
    Methods: Consecutive patients undergoing EVT for acute LVO ischemic stroke at the Sahlgrenska University Hospital from January 1st, 2015 to March 31st, 2018 were registered in the Sahlgrenska Stroke Recanalization Registry. Pre- and poststroke functional levels were assessed by the modified Rankin Scale (mRS). Outcomes were recanalization rate (mTICI = 2b/3), symptomatic intracranial hemorrhage [sICH], complications during hospital stay, and return to prestroke functional level and mortality at 3 months.
    Results: Among 591 patients, 90 had prestroke disability (mRS ≥ 3). The latter group were older, more often female, had more comorbidities and higher NIHSS scores before intervention compared to patients without prestroke disability. Recanalization rates (80.0% vs 85.0%, p = 0.211), sICH (2.2% vs 6.3% p = 0.086) and the proportion of patients returning to prestroke functional level (22.7% vs 14.8% p = 0.062) did not significantly differ between those with and without prestroke disability. Patients with prestroke disability had higher complication rates during hospital stay (55.2% vs 40.1% p < 0.01) and mortality at 3 months (48.9% vs 24.3% p < 0.001).
    Conclusion: One of five with prestroke disability treated with thrombectomy for a LVO ischemic stroke returned to their prestroke functional level. However, compared to patients without prestroke disability, mortality at 3 months was higher.
    MeSH term(s) Brain Ischemia/complications ; Brain Ischemia/surgery ; Endovascular Procedures ; Female ; Humans ; Ischemic Stroke ; Retrospective Studies ; Stroke/complications ; Stroke/surgery ; Thrombectomy ; Treatment Outcome
    Language English
    Publishing date 2020-05-14
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 187050-6
    ISSN 1432-1459 ; 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    ISSN (online) 1432-1459
    ISSN 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    DOI 10.1007/s00415-020-09882-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes.

    Douglas, Andrew / Fitzgerald, Seán / Mereuta, Oana Madalina / Rossi, Rosanna / O'Leary, Sean / Pandit, Abhay / McCarthy, Ray / Gilvarry, Michael / Holmegaard, Lukas / Abrahamsson, Margareta / Jerndal, Mikael / Dehlfors, Niclas / Brennan, Paul / Power, Sarah / O'Hare, Alan / Griffin, Emma / Kallmes, David F / Brinjikji, Waleed / Szikora, István /
    Tatlisumak, Turgut / Rentzos, Alexandros / Thornton, John / Doyle, Karen

    Journal of neurointerventional surgery

    2019  Volume 12, Issue 6, Page(s) 557–562

    Abstract: Background and aims: Platelets and von Willebrand factor (vWF) are key factors in thrombosis and thus are likely key components of acute ischemic stroke (AIS) emboli. We aimed to characterize platelet and vWF levels in AIS emboli and to assess ... ...

    Abstract Background and aims: Platelets and von Willebrand factor (vWF) are key factors in thrombosis and thus are likely key components of acute ischemic stroke (AIS) emboli. We aimed to characterize platelet and vWF levels in AIS emboli and to assess associations between their expression levels and clinical and procedural information.
    Materials and method: Histopathological and immunohistochemical analysis of emboli collected as part of the multi-institutional RESTORE registry was performed. The composition of the emboli was quantified using Orbit Image Analysis machine learning software. Correlations between clot components and clinical and procedural information were assessed using the χ
    Results: Ninety-one emboli samples retrieved from 63 patients were analyzed in the study. The mean platelet (CD42b) content of the clots was 33.9% and the mean vWF content of the clots was 29.8%. There was a positive correlation between platelet and vWF levels (ρ=0.564, p<0.001*, n=91). There was an inverse correlation between both platelets and vWF levels and percentage of red blood cells (RBCs) in the emboli (CD42b vs RBC: ρ=-0.535, p<0.001*, n=91; vWF vs RBC: ρ=-0.366, p<0.001*, n=91). Eighty-one percent of patients in the low platelet group had a good revascularization outcome (Thrombolysis in Cerebral Infarction 2c/3) compared with 58% in the high platelet group (χ
    Conclusion: Platelet and vWF levels in AIS emboli correlate with each other and both have an inverse relationship with RBC composition. Patients with platelet-rich clots have poorer revascularization outcomes.
    MeSH term(s) Blood Platelets/metabolism ; Brain Ischemia/blood ; Brain Ischemia/diagnostic imaging ; Brain Ischemia/surgery ; Cerebral Revascularization/trends ; Female ; Humans ; Machine Learning/trends ; Male ; Stroke/blood ; Stroke/diagnostic imaging ; Stroke/surgery ; Thromboembolism/blood ; Thromboembolism/diagnostic imaging ; Thromboembolism/surgery ; Treatment Outcome ; von Willebrand Factor/metabolism
    Chemical Substances von Willebrand Factor
    Language English
    Publishing date 2019-11-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 2514982-9
    ISSN 1759-8486 ; 1759-8478
    ISSN (online) 1759-8486
    ISSN 1759-8478
    DOI 10.1136/neurintsurg-2019-015410
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A systematic review and meta-analysis of erythropoietin in experimental stroke.

    Jerndal, Mikael / Forsberg, Kalle / Sena, Emily S / Macleod, Malcolm R / O'Collins, Victoria E / Linden, Thomas / Nilsson, Michael / Howells, David W

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

    2009  Volume 30, Issue 5, Page(s) 961–968

    Abstract: Erythropoietin (EPO) has shown promise as a neuroprotectant in animal models of ischemic stroke. EPO is thought not only to protect neurons from cell death, but also to promote regeneration after stroke. Here, we report a systematic review and meta- ... ...

    Abstract Erythropoietin (EPO) has shown promise as a neuroprotectant in animal models of ischemic stroke. EPO is thought not only to protect neurons from cell death, but also to promote regeneration after stroke. Here, we report a systematic review and meta-analysis of the efficacy of EPO in animal models of focal cerebral ischemia. Primary outcomes were infarct size and neurobehavioral outcome. Nineteen studies involving 346 animals for infarct size and 425 animals for neurobehavioral outcome met our inclusion criteria. Erythropoietin improved infarct size by 30.0% (95% CI: 21.3 to 38.8) and neurobehavioral outcome by 39.8% (33.7 to 45.9). Studies that randomized to treatment group or that blinded assessment of outcome showed lower efficacy. Erythropoietin was tested in animals with hypertension in no studies reporting infarct size and in 7.5% of the animals reporting neurobehavioral outcome. These findings show efficacy for EPO in experimental stroke, but when the impact of common sources of bias are considered, this efficacy falls, suggesting we may be overestimating its potential benefit. As common human co-morbidities may reduce therapeutic efficacy, broader testing to delineate the range of circumstances in which EPO works best would be beneficial.
    MeSH term(s) Animals ; Behavior, Animal/drug effects ; Brain Ischemia/drug therapy ; Brain Ischemia/pathology ; Databases, Factual ; Disease Models, Animal ; Erythropoietin/pharmacology ; Erythropoietin/therapeutic use ; Humans ; Hypertension/drug therapy ; Hypertension/pathology ; Neuroprotective Agents/pharmacology ; Neuroprotective Agents/therapeutic use ; Stroke/drug therapy ; Stroke/pathology
    Chemical Substances Neuroprotective Agents ; Erythropoietin (11096-26-7)
    Language English
    Publishing date 2009-12-30
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
    ZDB-ID 604628-9
    ISSN 1559-7016 ; 0271-678X
    ISSN (online) 1559-7016
    ISSN 0271-678X
    DOI 10.1038/jcbfm.2009.267
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top